Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Yi Han has a total of 66 co-authors. Here are the top co-authors by number of shared publications:

  • Dongjie Yan

    Department of Minimally Invasive Surgery, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing 101149, China

    2 shared publications
  • Feng Wang

    Department of Minimally Invasive Surgery, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing 101149, China

    2 shared publications
  • Hao Chen

    Department of Minimally Invasive Surgery, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing 101149, China

    2 shared publications
  • Nanying Che

    Department of Pathology, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing Chest Hospital, Capital Medical University, China

    2 shared publications
  • Qing Feng

    Yanda Hospital, Hebei Medical University, Hebei, China

    2 shared publications
  • Shiyan Yang

    Yanda Hospital, Hebei Medical University, Hebei, China

    2 shared publications

Latest Publications

  • Open Access

    Recurrence Pattern and Prognostic Value of Major Pathological Response in Patients with Locally Advanced Oesophageal Squamous Cell Carcinoma Treated with Neoadjuvant Immunochemotherapy: A Multicentre Retrospective Study

    by Feng Wang, Xiangyang Yu, Hao Chen, Dongjie Yan, Lei Yang, Ran Yang, Jianfei Zhu, Zhentao Yu, Yi Han

    Background/Objectives: Major pathological response (MPR) has been suggested as a potential surrogate marker for assessing the efficacy of neoadjuvant therapy. However, its prognostic value and association with postoperative recurrence patterns remain unclear in patients with locally advanced oesophageal squamous cell carcinoma (ESCC) treated with neoadjuvant immunochemotherapy. This multicentre study aimed to investigate the relationship between MPR status, survival outcomes, and recurrence characteristics in this population. Methods: A total of 305 patients with locally advanced ESCC who received neoadjuvant immunochemotherapy followed by surgical resection at four medical centres in China between December 2019 and April 2024 were retrospectively enrolled in this study. Prognostic factors for overall survival (OS) and recurrence-free survival (RFS) were analyzed using Cox proportional hazards regression models. Propensity score matching (PSM) was performed to balance baseline characteristics between patients with and without MPR, and survival outcomes and postoperative recurrence patterns were subsequently compared. Results: Among the 305 patients, 115 (37.7%) achieved MPR. Multivariate analysis identified MPR and the number of neoadjuvant treatment cycles as independent prognostic factors for both OS and RFS (p < 0.05). After PSM, patients with MPR showed significantly improved OS and RFS compared with those without (p < 0.05). Postoperative recurrence occurred less frequently in the MPR group than in the non-MPR group (13.9% vs. 42.1%, respectively; p < 0.05), with reductions in both locoregional and distant recurrence. Conclusions: In patients with locally advanced ESCC receiving neoadjuvant immunochemotherapy and surgery, achieving MPR is associated with improved survival outcomes and a lower risk of postoperative recurrence. MPR may serve as a useful prognostic indicator for this population.

  • Open Access

    Assessment of the necessity of interlobar lymph node dissection in pathological stage IB non-small cell lung cancer: a propensity score-matched study

    by Hao Chen, Dongjie Yan, Chunming Liu, Lanjun Zhang, Yi Han, Feng Wang

    Background Lung cancer is the leading cause of cancer-related deaths worldwide, with non-small cell lung cancer (NSCLC) being the most common type. Systematic lymph node dissection (SLND) is a standard procedure for NSCLC, but the necessity of routine interlobar lymph node dissection (ILND) in early-stage disease, particularly in stage IB NSCLC, remains debated. While ILND can be technically performed, its benefit in improving overall survival (OS) or recurrence-free survival (RFS) is unclear. The need for routine ILND remains controversial, with limited studies addressing its role in early-stage disease. This study aimed to assess whether ILND contributes to better survival outcomes in stage IB NSCLC. Methods We retrospectively analyzed 597 IB-stage NSCLC patients who underwent radical surgery for lung cancer at Sun Yat-Sen University Cancer Center from 1999 to 2009. We used the Cox proportional hazards regression model to analyze prognostic factors. After propensity-score matching (PSM), 458 patients were selected. We applied the Kaplan-Meier method and log-rank test to compare OS and RFS. Results Among 597 patients included in the study, 262 did not have ILND, while 335 did. According to whether the interlobar lymph nodes were dissected, 597 patients were divided into two groups. Significant differences were found between the two groups in laterality, number of dissected lymph node stations, and number of dissected lymph nodes (P < 0.05). Univariate and multivariate Cox analyses by the Cox proportional hazards model showed that age, family history of malignant tumors, and number of dissected lymph nodes were prognostic factors for OS (P < 0.05). For RFS, age and number of dissected lymph nodes were significant (P < 0.05). ILND was not associated with OS or RFS. After PSM, survival analysis using the Kaplan-Meier method and log-rank test showed no statistical association between ILND and OS or RFS (P > 0.05). Conclusion In stage IB NSCLC patients, ILND is not significantly associated with OS or RFS. Routine ILND is not necessary for early-stage NSCLC.

  • Open Access

    Survival and recurrence characteristics of patients with esophageal cancer with a pathological complete response after neoadjuvant immunochemotherapy followed by surgery: A multicenter propensity score matching study

    by Feng Wang, Xiangyang Yu, Dongjie Yan, Lei Yang, Jianfei Zhu, Ran Yang, Yi Han

    The relationship between pathological complete response (pCR) and survival as well as recurrence characteristics in patients with locally advanced esophageal squamous cell carcinoma (ESCC) undergoing neoadjuvant immunochemotherapy has not been frequently investigated. The present study primarily examined the survival and recurrence patterns of pCR in these patients. Data were collected from 300 individuals diagnosed with stage II‑III ESCC who underwent neoadjuvant immunochemotherapy followed by surgery across four medical centers between 2019 and 2024. The Cox proportional hazards model and the Kaplan‑Meier method with propensity score matching (PSM) were utilized for survival analysis to examine the relationship between pCR and overall survival (OS) and recurrence‑free survival (RFS). The recurrence patterns among patients were evaluated. Of the 300 patients included in the present study, 80 achieved a pCR. Univariate and multivariate analyses utilizing the Cox proportional hazards model demonstrated that pCR was a statistically significant prognostic factor for OS and RFS (P<0.05). Utilizing PSM based on the achievement of pCR, survival analysis conducted using the Kaplan‑Meier method and log‑rank test demonstrated that patients in the pCR group exhibited significantly improved RFS (P0.05). The recurrence rate in the pCR group was 11.2%, with a local recurrence rate of 7.5% and a distant recurrence rate of 3.7%. Both rates were significantly decreased compared with those in the non‑pCR group (P<0.05). The mediastinal lymph node represented the most common site of recurrence in both groups. In patients with ESCC undergoing neoadjuvant immunochemotherapy, pCR indicated improved OS and RFS; however, the association between pCR and OS was not statistically significant. Concurrently, pCR was associated with reduced local and distant recurrence rates, and the recurrence pattern of patients in the pCR group differed from that of patients in the non‑pCR group. Future research should involve larger sample sizes to elucidate the relationship between pCR and survival, as well as its influence on recurrence patterns.


  • Open Access

    Three-dimensional printed titanium chest wall reconstruction for tumor removal in the sternal region

    by Wenzhang Wang, Shiyan Yang, Menghu Han, Haifeng Liu, Qing Feng, Yonglin Su, Yi Han, Jin Wang

    Resection of thoracic wall tumors results in significant defects in the chest wall, leading to various complications. In recent years, the use of three-dimensional (3D) printed titanium alloy prostheses in clinical practice has demonstrated enhanced outcomes in chest wall reconstruction surgery. A cohort of seven patients with sternal tumors was identified for this study. Following a helical CT scan, a digital model was generated for the design of the prosthesis. Subsequently, the tumors were then removed together with the affected sternum and ribs. The chest wall was then reconstructed using 3D-printed titanium alloy prosthesis for bone reconstruction, mesh for pleural reconstruction, and flap for soft tissue reconstruction. Patients were monitored for a period of one year post-surgery. In the seven cases examined, the tumors were found in various locations with varying degrees of invasion. Based on the scope of surgical resection and the size of the defect, 3D-printed titanium alloy prosthesis was custom-designed for chest wall reconstruction. Prior to bone reconstruction, pleural reconstruction was achieved with Bard Composix E/X Mesh, while soft tissue repair involved muscle flap and musculocutaneous flap procedures. A one-year follow-up assessment revealed that the utilization of the 3D-printed titanium alloy prosthesis led to secure fixation, favorable histocompatibility, and enhanced lung function. The findings demonstrate that the utilization of 3D printed titanium alloy prostheses represents a significant advancement in the field of chest wall reconstruction and thoracic surgical procedures.


  • Open Access

    T-cell subsets and cytokines are indicative of neoadjuvant chemoimmunotherapy responses in NSCLC

    by Ling Yi, Ziwei Xu, Tianyu Ma, Chong Wang, Panjian Wei, Bo Xiao, Hongtao Zhang, Nanying Che, Zhidong Liu, Yi Han

    Purpose: Neoadjuvant PD-1 blockade combined with chemotherapy is a promising treatment for resectable non-small cell lung cancer (NSCLC), yet the immunological mechanisms contributing to tumor regression and biomarkers corresponding to different pathological responses remain unclear. Methods: Using dynamic and paired blood samples from NSCLC patients receiving neoadjuvant chemoimmunotherapy, we analyzed the frequencies of CD8 + T-cell and Treg subsets and their dynamic changes during neoadjuvant treatment through flow cytometry. Cytokine profiles and function-related gene expression of CD8 + T cells and Tregs were analyzed through flow cytometry and mRNA-seq. Infiltrating T-cell subsets in resected tissues from patients with different pathological responses were analyzed through multiplex immunofluorescence. Results: Forty-two NSCLC patients receiving neoadjuvant chemoimmunotherapy were enrolled and then underwent surgical resection and pathological evaluation. Nineteen patients had pCR (45%), 7 patients had MPR (17%), and 16 patients had non-MPR (38%). In patients with pCR, the frequencies of CD137 + CD8 + T cells (P = 0.0475), PD-1 + Ki-67 + CD8 + T cells (P = 0.0261) and Tregs (P = 0.0317) were significantly different from those of non-pCR patients before treatment. pCR patients usually had low frequencies of CD137 + CD8 + T cells, PD-1 + Ki-67 + CD8 + T cells and Tregs, and their AUCs were higher than that of tissue PD-L1 expression. Neoadjuvant chemoimmunotherapy markedly improved CD8 + T-cell proliferation and activation, especially in pCR patients, as the frequencies of CD137 + CD8 + (P = 0.0136) and Ki-67 + CD8 + (P = 0.0391) T cells were significantly increased. The blood levels of cytokines such as IL-2 (P = 0.0391) and CXCL10 (P = 0.0195) were also significantly increased in the pCR group, which is consistent with the high density of activated cytotoxic T cells at the tumor site (P < 0.0001). Conclusion: Neoadjuvant chemoimmunotherapy drives CD8 + T cells toward a proliferative and active profile. The frequencies of CD137 + CD8 + T cells, PD-1 + Ki-67 + CD8 + T cells and Tregs at baseline might predict the response to neoadjuvant chemoimmunotherapy in NSCLC patients. The increase in IL-2 and CXCL10 might reflect the chemotaxis and enrichment of cytotoxic T cells at the tumor site and a better response to neoadjuvant chemoimmunotherapy.


  • Open Access

    Easily applicable predictive score for MPR based on parameters before neoadjuvant chemoimmunotherapy in operable NSCLC: a single-center, ambispective, observational study

    by Mingming Hu, Xiaomi Li, Haifeng Lin, Baohua Lu, Qunhui Wang, Li Tong, Hongxia Li, Nanying Che, Shaojun Hung, Yi Han, et al.

    Background: Neoadjuvant chemoimmunotherapy (NACI) is promising for resectable nonsmall cell lung cancer (NSCLC), but predictive biomarkers are still lacking. The authors aimed to develop a model based on pretreatment parameters to predict major pathological response (MPR) for such an approach. Methods: The authors enrolled operable NSCLC treated with NACI between March 2020 and May 2023 and then collected baseline clinical-pathology data and routine laboratory examinations before treatment. The efficacy and safety data of this cohort was reported and variables were screened by Logistic and Lasso regression and nomogram was developed. In addition, receiver operating characteristic curves, calibration curves, and decision curve analysis were used to assess its power. Finally, internal cross-validation and external validation was performed to assess the power of the model. Results: In total, 206 eligible patients were recruited in this study and 53.4% (110/206) patients achieved MPR. Using multivariate analysis, the predictive model was constructed by seven variables, prothrombin time (PT), neutrophil percentage (NEUT%), large platelet ratio (P-LCR), eosinophil percentage (EOS%), smoking, pathological type, and programmed death ligand-1 (PD-L1) expression finally. The model had good discrimination, with area under the receiver operating characteristic curve (AUC) of 0.775, 0.746, and 0.835 for all datasets, cross-validation, and external validation, respectively. The calibration curves showed good consistency, and decision curve analysis indicated its potential value in clinical practice. Conclusion: This real world study revealed favorable efficacy in operable NSCLC treated with NACI. The proposed model based on multiple clinically accessible parameters could effectively predict MPR probability and could be a powerful tool in personalized medication.


  • Open Access

    Three‐dimensional (3D)‐printed titanium sternum replacement: A case report

    by Wenzhang Wang, Zhaoru Liang, Shiyan Yang, Qing Feng, Xuewei Nie, Guang Su, Wenjie Yuan, Yi Han

    After sternal tumor resection, reconstruction of chest wall defects is still a challenging part of thoracic surgery. Three‐dimensional (3D)‐printed titanium alloy prosthesis implants provide an effective solution. The bionic bone trabecular micropore structure, which is beneficial to the human body, increases stability and robustness of the prosthesis. Here, we report a successful case of a customized prosthesis using a 3D‐printed titanium alloy to repair and reconstruct bone defects in a patient with sternal osteosarcoma who underwent radical resection of the whole sternum.


  • Open Access

    Video-assisted thoracic bronchial sleeve lobectomy with bronchoplasty for treatment of lung cancer confined to a single lung lobe: a case series of Chinese patients

    by Daping Yu, Yi Han, Shijie Zhou, Xiaoyun Song, Yunsong Li, Ning Xiao, Zhidong Liu

    The outcomes of video-assisted thoracic bronchial sleeve lobectomy (VABSL), a minimally invasive video-assisted thoracoscopic (VATS) lobectomy, are mostly unknown in Chinese patients.


  • Open Access

    Analysis of ICU Treatment on Resection of Giant Tumors in the Mediastinum of the Thoracic Cavity

    by Nai-Min Kang, Ning Xiao, Xiao-Jun Sun, Yi Han, Bao-Jian Luo, Zhi-Dong Liu

    Analysis of ICU Treatment on Resection of Giant Tumors in the Mediastinum of the Thoracic Cavity Giant tumor in mediastinum of thoracic cavity;ICU;treatment during the peri-operative period; Objective: The purpose of this study was to assess prognosis after resection of giant tumors (including lobectomy or pneumonectomy) in the mediastinum. Materials and Methods: Patients with resection of a giant tumor in the mediastinum of the thoracic cavity received ICU treatment including dynamic monitoring of vital signs, arterial blood pressure and CVP detection, determination of hemorrhage, pulmonary function and blood gas assay, treatment of relevant complications, examination and treatment with fiber optic bronchoscopy, transfusion and hemostasis as well as postoperative removal of ventilators by invasive and non-invasive sequential mechanical ventilation technologies. Results: Six patients were rehabilitated successfully after ICU treatment with controlled postoperative errhysis and pulmonary infection by examination and treatment with fiber optic bronchoscopy without second application of ventilators and tubes after sequential mechanical ventilation technology. One patient died from multiple organ failure under ICU treatment due to postoperative active hemorrhage after second operative hemostasis. Conclusions: During peri-operative period of resection of giant tumor (including lobectomy or pneumonectomy) in mediastinum ofthe thoracic cavity, the ICU plays an important role in dynamic monitoring of vital signs, treatment of postoperative stress state, postoperative hemostasis and successful removal of ventilators after sequential mechanical ventilation.